Literature DB >> 1530656

Stereospecific reduction of haloperidol in human tissues.

D W Eyles1, S M Pond.   

Abstract

In the current study, we have examined the catalytic activity and stereospecificity of haloperidol (HP) reductase activity in the cytosolic fractions of human brain and liver and in whole blood. The reductase activity was NADPH-dependent and inhibited by menadione, features typical of the ketone reductases (EC 1.2.1). The Vmax in the brain was about 4-fold higher than in the liver. Moreover, the reaction was stereospecific in that only the S(-) enantiomer was detected in brain and blood and 99.2 +/- 0.1% of the reduced HP (RHP) produced in the liver was S(-). The potential clinical implications of our results are unknown because until now all binding and pharmacodynamic studies with RHP have been performed with the racemate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530656     DOI: 10.1016/0006-2952(92)90117-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Formation of pyridinium species of haloperidol in human liver and brain.

Authors:  D W Eyles; J J McGrath; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

Review 2.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

3.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 4.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

5.  Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.

Authors:  D W Eyles; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

Review 6.  Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Authors:  Peng Li; Gretchen L Snyder; Kimberly E Vanover
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.